Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening

MARIA MAGKANA, PANAGIOTA MENTZELOPOULOU, EKATERINI MAGKANA, ANDREAS PAMPANOS, NIKOLAOS VRACHNIS, ELENI KALAFATI, GEORGIOS DASKALAKIS, EKATERINI DOMALI, NIKOLAOS THOMAKOS, ALEXANDROS RODOLAKIS, NICHOLAS P. ANAGNOU and KALLIOPI I. PAPPA
Anticancer Research May 2022, 42 (5) 2599-2606; DOI: https://doi.org/10.21873/anticanres.15738
MARIA MAGKANA
1School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
2Department of Genetics, Alexandra Hospital, Athens, Greece;
3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mmagkana@hotmail.com
PANAGIOTA MENTZELOPOULOU
4Department of Cytology, Alexandra Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EKATERINI MAGKANA
4Department of Cytology, Alexandra Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREAS PAMPANOS
2Department of Genetics, Alexandra Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS VRACHNIS
5Third Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ELENI KALAFATI
3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGIOS DASKALAKIS
6First Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EKATERINI DOMALI
6First Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS THOMAKOS
6First Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDROS RODOLAKIS
6First Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICHOLAS P. ANAGNOU
3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KALLIOPI I. PAPPA
3Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece;
6First Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: To evaluate p16/Ki-67 dual-staining performance for detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in the management of women with minor cervical abnormalities. Patients and Methods: All 759 enrolled patients were tested for cytology, high-risk human papillomavirus (HR-HPV) and dual p16/Ki-67 staining. Results: Positivity rates for HR-HPV and dual staining increased as dysplasia was worsened from non-CIN (37.6% and 0%) to CIN1 (62.5% and 1.6%) and CIN2+ (98.7% and 97.3%), respectively. HPV18 and HPV16 exhibited the highest odds ratios (53.16 and 11.31) in the CIN2+ group. Both p16/Ki-67 dual staining and HR-HPV presented similar sensitivities (97.3% and 98.7%, respectively) for CIN2+ detection. Dual staining specificity, however, was 99.3%, significantly higher compared to HR-HPV testing (52.2%). The utility of dual staining was evaluated in different screening strategies and appeared to reduce the number of colposcopies required for the detection of CIN2+ cases. Conclusion: p16/Ki-67 dual-staining cytology is a surrogate triage biomarker in cytology-based screening programs, with high performance for efficient risk stratification of women with mild cervical abnormalities.

Key Words:
  • HPV
  • cervical cancer
  • p16/Ki-67 dual-stained cytology
  • triage
  • CIN2
  • CIN3
  • HSIL
  • screening
  • risk stratification
  • Pap test
  • Received March 1, 2022.
  • Revision received March 24, 2022.
  • Accepted March 25, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (5)
Anticancer Research
Vol. 42, Issue 5
May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 17 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening
MARIA MAGKANA, PANAGIOTA MENTZELOPOULOU, EKATERINI MAGKANA, ANDREAS PAMPANOS, NIKOLAOS VRACHNIS, ELENI KALAFATI, GEORGIOS DASKALAKIS, EKATERINI DOMALI, NIKOLAOS THOMAKOS, ALEXANDROS RODOLAKIS, NICHOLAS P. ANAGNOU, KALLIOPI I. PAPPA
Anticancer Research May 2022, 42 (5) 2599-2606; DOI: 10.21873/anticanres.15738

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening
MARIA MAGKANA, PANAGIOTA MENTZELOPOULOU, EKATERINI MAGKANA, ANDREAS PAMPANOS, NIKOLAOS VRACHNIS, ELENI KALAFATI, GEORGIOS DASKALAKIS, EKATERINI DOMALI, NIKOLAOS THOMAKOS, ALEXANDROS RODOLAKIS, NICHOLAS P. ANAGNOU, KALLIOPI I. PAPPA
Anticancer Research May 2022, 42 (5) 2599-2606; DOI: 10.21873/anticanres.15738
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • HPV
  • cervical cancer
  • p16/Ki-67 dual-stained cytology
  • triage
  • CIN2
  • CIN3
  • HSIL
  • screening
  • risk stratification
  • Pap test
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire